和铂医药成立Élancé Therapeutics，推进下一代肥胖症疗法的发展-动脉网

Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

CISION 等信源发布 2025-03-12 12:41



可切换为仅中文







- Élancé Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but preserve and even increase muscle and lean mass

- Élancé Therapeutics 旨在改进当前的肥胖症治疗，特别是增加总体体重和脂肪量的减少，同时保留甚至增加肌肉和瘦体质量。

- Élancé Therapeutics will leverage HCAb-based bispecific antibody technology to advance these next-generation therapies

- Élancé Therapeutics 将利用基于 HCAb 的双特异性抗体技术来推进这些下一代疗法。

- Élancé will refine and expand Hu-mAtrIx

Élancé 将完善并扩展 Hu-mAtrIx。

商标

AI platform to empower multiple bispecific antibody discovery programs

用于赋能多个双特异性抗体发现项目的AI平台

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

ROTTERDAM, Netherlands

荷兰鹿特丹

and

和

SHANGHAI

上海

，

March 12, 2025

2025年3月12日

/PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology, today announced the launch of Élancé Therapeutics ('Élancé'). Harnessing Harbour BioMed's proprietary HCAb-based bispecific antibody technology, Élancé aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle preservation and long-term efficacy..

/PRNewswire/ -- 和铂医药（港交所代码：02142），一家致力于免疫学和肿瘤学领域新型抗体疗法的发现、开发和商业化的全球生物制药公司，今日宣布推出 Élancé Therapeutics（“Élancé”）。利用和铂医药专有的基于 HCAb 的双特异性抗体技术，Élancé 致力于开发创新疗法，以应对当前肥胖治疗中的关键挑战，包括肌肉保护和长期疗效。

Obesity affects nearly one billion people worldwide and is associated with serious health complications, yet current treatments remain inadequate for many patients. Despite recent advancements, challenges such as limited efficacy, lean mass loss, and post-treatment weight regain highlight the need for novel approaches that offer sustained benefits and better clinical outcome..

肥胖影响着全球近十亿人，并与严重的健康并发症相关，但目前的治疗方法对许多患者来说仍然不足。尽管最近有所进展，但疗效有限、瘦体重减少以及治疗后体重反弹等问题凸显了需要新的方法来提供持久的益处和更好的临床结果。

To address these gaps, Élancé is building a pipeline of bispecific antibody programs designed to improve weight loss outcomes while preserving lean muscle mass. By integrating dual-targeting strategies with enhanced safety profiles, these therapies have the potential to complement and expand upon existing treatment options, including various agonists of .

为了弥补这些不足，Élancé 正在构建一系列双特异性抗体项目，旨在改善减重效果的同时保留瘦肌肉质量。通过将双重靶向策略与更高的安全性相结合，这些疗法有潜力补充并扩展现有的治疗选择，包括多种激动剂。

GLP-1

receptor, GIP receptor, and GCG receptor.

受体、GIP受体和GCG受体。

Élancé's pipeline includes multiple bispecific antibody programs in preclinical development, each designed to offer innovative mechanisms of action, including targeted hormone modulation and enhanced metabolic regulation. These programs are supported by Harbour BioMed's validated HCAb-based bispecific antibody discovery platform, which has been successfully applied across multiple therapeutic areas.

Élancé的管线包括多个处于临床前开发阶段的双特异性抗体项目，每个项目都旨在提供创新的作用机制，包括靶向激素调节和增强的代谢调控。这些项目得到了 Harbour BioMed 验证过的基于HCAb的双特异性抗体发现平台的支持，该平台已成功应用于多个治疗领域。

In addition, Élancé will refine and expand Nona Biosciences' Hu-mAtrIx.

此外，Élancé 将完善并扩展 Nona Biosciences 的 Hu-mAtrIx。

商标

AI platform to support bispecific antibody discovery, with AI applications guiding antibody sequence discovery, enrichment, optimization, bispecific geometry design, and developability/immunogenicity/pharmacokinetics (PK) assessments, as well as patient biomarker studies.

支持双特异性抗体发现的人工智能平台，人工智能应用指导抗体序列发现、富集、优化、双特异性几何设计、可开发性/免疫原性/药代动力学 (PK) 评估，以及患者生物标志物研究。

'Our bispecific antibody programs enable a new paradigm in obesity treatment by targeting multiple pathways in a precise and effective manner,' said

“我们的双特异性抗体项目通过精确且有效的方式靶向多条通路，为肥胖症治疗提供了新的范式，”

Jingsong Wang

王京松

, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed. 'With a focus on optimizing weight loss efficacy, preserving lean muscle mass, and improving long-term outcomes, we believe our approach has the potential to redefine obesity therapeutics.'

医学博士， Harbour BioMed 创始人、董事长兼首席执行官。“通过专注于优化减重效果、保持瘦肌肉质量和改善长期结果，我们相信我们的方法有潜力重新定义肥胖症治疗。”

About Harbour BioMed

关于和铂医药

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions..

和铂医药（股票代码：02142.HK）是一家全球性生物制药公司，致力于发现、开发和商业化针对免疫学和肿瘤学领域的新型抗体疗法。公司通过内部研发能力、与共同发现和共同开发合作伙伴的合作以及选择性收购，构建其强大的产品组合和差异化的研发管线。

The proprietary antibody technology platform Harbour Mice

专有的抗体技术平台 Harbour Mice

generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE

生成完全人源的单克隆抗体，采用两条重链和两条轻链（H2L2）格式，以及仅重链（HCAb）格式。基于HCAb抗体，构建了基于HCAb的免疫细胞接合器（HBICE）。

) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice

`) 双特异性抗体技术能够提供传统联合疗法无法实现的肿瘤杀伤效果。整合 Harbour Mice`

, and HBICE

，以及HBICE

with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to

通过单一的B细胞克隆平台，我们的抗体发现引擎在开发下一代治疗性抗体方面具有高度的独特性和高效性。欲了解更多信息，请参阅

www.harbourbiomed.com

。

About Élancé Therapeutics

关于Élancé Therapeutics

Élancé Therapeutics is a biotechnology company developing next-generation biologics for obesity treatment. Incubated by Harbour BioMed, Élancé Therapeutics leverages advanced bispecific antibody technology to address key challenges in obesity management, including limited efficacy, lean mass loss, and post-treatment weight regain.

Élancé Therapeutics是一家生物技术公司，致力于开发用于治疗肥胖症的下一代生物制剂。该公司由 Harbour BioMed 孵化，利用先进的双特异性抗体技术解决肥胖管理中的关键挑战，包括疗效有限、瘦体重减少以及治疗后体重反弹等问题。

With a pipeline of innovative bispecific antibody programs targeting novel pathways, the company aims to provide effective and sustainable treatment solutions that complement existing obesity therapies..

通过一条针对新途径的创新双特异性抗体项目管线，该公司旨在提供有效且可持续的治疗解决方案，以补充现有的肥胖症疗法。

SOURCE Harbour BioMed

来源：和铂医药

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers